Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2007 1
2008 1
2009 1
2020 1
2021 2
2022 0
Text availability
Article attribute
Article type
Publication date

Search Results

5 results
Results by year
Filters applied: . Clear all
Page 1
Emerging potential of cannabidiol in reversing proteinopathies.
Dash R, Ali MC, Jahan I, Munni YA, Mitra S, Hannan MA, Timalsina B, Oktaviani DF, Choi HJ, Moon IS. Dash R, et al. Ageing Res Rev. 2021 Jan;65:101209. doi: 10.1016/j.arr.2020.101209. Epub 2020 Nov 9. Ageing Res Rev. 2021. PMID: 33181336 Review.
The aberrant accumulation of disease-specific protein aggregates accompanying cognitive decline is a pathological hallmark of age-associated neurological disorders, also termed as proteinopathies, including Alzheimer's disease, Parkinson's disease, Huntington's
The aberrant accumulation of disease-specific protein aggregates accompanying cognitive decline is a pathological hallmark of age-associated …
Cannabidiol: a prion therapy for mice?
Dicou E. Dicou E. J Neurosci Res. 2008 May 1;86(6):1417-8. doi: 10.1002/jnr.21694. J Neurosci Res. 2008. PMID: 18338806 No abstract available.
Nonpsychoactive cannabidiol prevents prion accumulation and protects neurons against prion toxicity.
Dirikoc S, Priola SA, Marella M, Zsürger N, Chabry J. Dirikoc S, et al. J Neurosci. 2007 Sep 5;27(36):9537-44. doi: 10.1523/JNEUROSCI.1942-07.2007. J Neurosci. 2007. PMID: 17804615 Free PMC article.
Prion diseases are transmissible neurodegenerative disorders characterized by the accumulation in the CNS of the protease-resistant prion protein (PrPres), a structurally misfolded isoform of its physiological counterpart PrPsen. Both neuropathogenesis and prion
Prion diseases are transmissible neurodegenerative disorders characterized by the accumulation in the CNS of the protease-resistant
Cannabidiol: a promising drug for neurodegenerative disorders?
Iuvone T, Esposito G, De Filippis D, Scuderi C, Steardo L. Iuvone T, et al. CNS Neurosci Ther. 2009 Winter;15(1):65-75. doi: 10.1111/j.1755-5949.2008.00065.x. CNS Neurosci Ther. 2009. PMID: 19228180 Free PMC article. Review.
In this contest, marijuana derivatives have attracted special interest, although these compounds have always raised several practical and ethical problems for their potential abuse. Nevertheless, among Cannabis compounds, cannabidiol (CBD), which lacks any unwanted psychot …
In this contest, marijuana derivatives have attracted special interest, although these compounds have always raised several practical and et …
Medium-throughput zebrafish optogenetic platform identifies deficits in subsequent neural activity following brief early exposure to cannabidiol and Δ9-tetrahydrocannabinol.
Kanyo R, Amin MR, Locskai LF, Bouvier DD, Olthuis AM, Allison WT, Ali DW. Kanyo R, et al. Sci Rep. 2021 Jun 1;11(1):11515. doi: 10.1038/s41598-021-90902-3. Sci Rep. 2021. PMID: 34075141 Free PMC article.
In light of legislative changes and the widespread use of cannabis as a recreational and medicinal drug, delayed effects of cannabis upon brief exposure during embryonic development are of high interest as early pregnancies often go undetected. Here, zebrafish embryos were expose …
In light of legislative changes and the widespread use of cannabis as a recreational and medicinal drug, delayed effects of cannabis upon br …